Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 May 15;61(10):1577-1580.
doi: 10.2169/internalmedicine.8168-21. Epub 2021 Oct 26.

Rhabdomyolysis Caused by Gefitinib Overdose

Shohei Obayashi  1 , Katsuyoshi Tomomatsu  1 , Mika Urata  1 , Jun Tanaka  1 , Kyoko Niimi  1 , Naoki Hayama  1 , Tsuyoshi Oguma  1 , Koichiro Asano  1 , Yoko Ito  1
Affiliations
Case Reports

Rhabdomyolysis Caused by Gefitinib Overdose

Shohei Obayashi et al. Intern Med. .

Abstract

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are common therapeutic agents for EGFR mutation-positive advanced non-small-cell lung cancer. There has been no report of rhabdomyolysis caused by an overdose of EGFR-TKIs. We herein review the existing literature on the subject and report a rare case of rhabdomyolysis due to an overdose of gefitinib, an EGFR-TKI.

Keywords: EGFR-TKI; overdose; rhabdomyolysis.

PubMed Disclaimer

Conflict of interest statement

The authors state that they have no Conflict of Interest (COI).

Figures

Figure 1.
Figure 1.
Chest X-Ray and CT scans: (a) before treatment with gefitinib, (b) when the patient visited emergency room.
Figure 2.
Figure 2.
Time course line graph of gefitinib plasma concentration after taking a high dose (1,500 mg: our case) combined with those after taking a single dose of 225 mg gefitinib obtained from pharmaceutical interview form for gefitinib.
Figure 3.
Figure 3.
Time course line graph of CK, amylase (left), ALT, and AST concentrations after hospitalization (right).
See this image and copyright information in PMC

References

    1. Akechi T, Okamura H, Nishiwaki Y, Uchitomi Y. Psychiatric disorders and associated and predictive factors in patients with unresectable nonsmall cell lung carcinoma: a longitudinal study. Cancer 92: 2609-2622, 2001. - PubMed
    1. Koršić M, Muršić D, Badovinac S, et al. . Erlotinib-related rhabdomyolysis: the role of pharmacogenetics and drug-drug interaction. Cancer Chemother Pharmacol 76: 1317-1319, 2015. - PubMed
    1. Ishikawa R, Yoneyama R, Miyajima K, et al. . 2 cases that afatinib was considered as a cover suspicion medicine for rhabdomyolysis. Jpn J Lung Cancer 56: 663, 2016.
    1. Rahouma M, Kamel M, Abouarab A, et al. . Lung cancer patients have the highest malignancy-associated suicide rate in USA: a population-based analysis. Ecancermedicalscience 12: 859, 2018. - PMC - PubMed
    1. Temel JS, Greer JA, Muzikansky A, et al. . Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363: 733-742, 2010. - PubMed

Publication types

MeSH terms